STERIS Plc (Ireland) 10-Q 9 Feb 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2015	Jan. 29, 2016
Entity Information [Line Items]
Entity Registrant Name	STERIS PLC
Entity Central Index Key	1,624,899
Document Type	10-Q
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		85,898,484

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Allowance for Doubtful Accounts Receivable, Current	$ 10,759	$ 9,415
Preferred Stock, Par or Stated Value Per Share	$ 0.15	$ 0
Current assets:
Cash and cash equivalents	$ 231,360	$ 167,689
Accounts receivable (net of allowances of $10,759 and $9,415, respectively)	440,858	325,289
Inventories, net	208,306	160,818
Deferred income taxes, net	30,362	31,629
Prepaid expenses and other current assets	54,822	35,007
Total current assets	965,708	720,432
Property, plant, and equipment, net	1,053,132	493,053
Intangible Assets, Net (Including Goodwill)	3,309,177	860,645
Other assets	22,266	23,161
Total assets	5,350,283	2,097,291
Current liabilities:
Accounts payable	116,336	99,340
Accrued Income Taxes, Current	0	7,154
Accrued payroll and other related liabilities	90,967	74,805
Accrued expenses and other	152,667	102,032
Total current liabilities	359,970	283,331
Long-term indebtedness	1,639,461	621,075
Deferred income taxes, net	276,336	71,905
Other Liabilities, Noncurrent	84,693	47,334
Total liabilities	$ 2,360,460	$ 1,023,645
Commitments and contingencies (see note 9)
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding	$ 15	$ 0
Ordinary shares, with $0.15 par value; 170,060 shares authorized and common shares with no par value; 300,000 shares authorized; 85,885 ordinary and 70,040 common shares issued; 85,879 ordinary and 59,675 common shares outstanding, respectively	1,846,700	264,853
Shares held in treasury, 0 and 10,364 shares, respectively	0	(320,343)
Retained earnings	1,203,086	1,193,791
Accumulated other comprehensive income	(74,422)	(66,669)
Total shareholders' equity	2,975,379	1,071,632
Noncontrolling interest	14,444	2,014
Total equity	2,989,823	1,073,646
Total liabilities and equity	$ 5,350,283	$ 2,097,291
Preferred Stock, Shares Authorized	100,000	0
Preferred Stock, Shares Issued	100,000	0
Preferred Stock, Shares Outstanding	100,000	0
Common Stock, No Par Value	$ 0	$ 0
Common Stock, Shares Authorized	170,060,000	300,000,000
Common Stock, Shares, Issued	85,885,000	70,040,000
Common Stock, Shares, Outstanding	85,879,000	59,675,000
Common Stock, Par or Stated Value Per Share	$ 0.15	$ 0
Common shares held in treasury, shares	0	10,364,404

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Accounts Receivable Allowances	$ 10,759	$ 9,415
Preferred Stock, Par or Stated Value Per Share	$ 0.15	$ 0
Serial preferred shares authorized	100,000	0
Serial preferred shares issued	100,000	0
Preferred Stock, Shares Outstanding	100,000	0
Common shares without par value	$ 0	$ 0
Common shares authorized	170,060,000	300,000,000
Common shares issued	85,885,000	70,040,000
Common shares outstanding	85,879,000	59,675,000
Common Stock, Par or Stated Value Per Share	$ 0.15	$ 0
Common shares held in treasury, shares	0	10,364,404

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Product	$ 305,156	$ 267,285	$ 811,608	$ 754,570
Service	313,532	205,959	736,879	594,046
Total revenues	618,688	473,244	1,548,487	1,348,616
Cost of revenues:
Product	165,575	150,164	443,519	423,130
Service	214,932	125,924	473,376	364,245
Total cost of revenues	380,507	276,088	916,895	787,375
Gross Profit	238,181	197,156	631,592	561,241
Operating expenses:
Selling, general, and administrative	177,319	122,370	476,613	362,350
Research and development	14,334	14,549	42,354	39,964
Restructuring Costs	(194)	(1,109)	(976)	(10)
Total operating expenses	191,459	135,810	517,991	402,304
Income (loss) from operations	46,722	61,346	113,601	158,937
Non-operating expenses, net:
Interest expense	17,706	4,822	31,312	14,452
Interest income and miscellaneous expense	(406)	(417)	(1,116)	(673)
Total non-operating expenses, net	17,300	4,405	30,196	13,779
Income (loss) before income tax expense (benefit)	29,422	56,941	83,405	145,158
Income tax expense (benefit)	8,268	18,817	29,689	51,493
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	21,154	38,124	53,716	93,665
Net Income (Loss) Attributable to Noncontrolling Interest	1,109	0	693	0
Net (loss) income	$ 20,045	$ 38,124	$ 53,023	$ 93,665
Net income (loss) per common share
Basic	$ 0.26	$ 0.64	$ 0.81	$ 1.58
Diluted	0.26	0.63	0.80	1.56
Cash dividends declared per common share outstanding	$ 0.25	$ 0.23	$ 0.73	$ 0.67

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 21,154	$ 38,124	$ 53,716	$ 93,665
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax	(233)	(137)	(468)	(412)
Other Comprehensive (Income) Loss, Amortization Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax	0	0	10,563	0
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax	6	172	251	172
Net Income (Loss) Attributable to Noncontrolling Interest	1,109	0	693	0
Net (loss) income	20,045	38,124	53,023	93,665
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	11	(569)	(1,389)	(510)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	(377)	(222)	(757)	(665)
Other Comprehensive Income (Loss), Finalization of Pension and Other Postretirement Benefit Plan Valuation, Net of Tax	0	0	17,029	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(14,593)	(18,806)	(22,636)	(35,497)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(14,959)	(19,597)	(7,753)	(36,672)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ 5,086	$ 18,527	$ 45,270	$ 56,993

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 53,716	$ 93,665
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, depletion, and amortization	90,925	69,440
Deferred income taxes	(3,037)	344
Share-based compensation	12,240	11,409
Pension Expense	26,470	0
Pension Contributions	(4,641)	0
Loss on the disposal of property, plant, equipment, and intangibles, net	352	(400)
Excess Tax Benefit from Share-based Compensation, Operating Activities	(5,909)	(8,880)
Other items	(18,163)	(5,392)
Changes in operating assets and liabilities:
Accounts receivable, net	(3,070)	29,192
Inventories, net	(15,481)	(27,014)
Other current assets	(5,070)	6,287
Accounts payable	(17,893)	(25,215)
Accruals and other, net	(5,820)	21,774
Net cash provided by operating activities	104,619	165,210
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(82,117)	(56,757)
Proceeds from the sale of property, plant, equipment, and intangibles	400	812
Payments to Acquire Investments	0	(4,681)
Investments in businesses, net of cash acquired	(604,682)	(182,692)
Net cash used in investing activities	(686,399)	(243,318)
Financing activities:
Proceeds from Issuance of Private Placement	350,000	0
Proceeds from (Repayments of) Lines of Credit	348,670	117,200
Payments of Financing Costs	(5,094)	(7,347)
Repurchases of common shares	(14,069)	(20,110)
Cash dividends paid to common shareholders	(43,728)	(39,790)
Proceeds from Issuance or Sale of Equity	488	0
Stock option and other equity transactions, net	10,944	19,245
Excess Tax Benefit from Share-based Compensation, Financing Activities	5,909	8,880
Net cash used in financing activities	653,120	78,078
Effect of exchange rate changes on cash and cash equivalents	(7,669)	(8,260)
(Decrease) increase in cash and cash equivalents	63,671	(8,290)
Cash and cash equivalents at beginning of period	167,689	152,802
Cash and cash equivalents at end of period	$ 231,360	$ 144,512

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	Nature of Operations and Summary of Significant Accounting Policies Nature of Operations STERIS plc, a public limited company organized under the laws of England and Wales, was incorporated on October 9, 2014 as a private limited company under the name New STERIS Limited and was re-registered effective November 2, 2015 as a public limited company under the name STERIS plc. New STERIS Limited was established to effect the combination (“Combination”) of STERIS Corporation, an Ohio corporation (“Old STERIS”), and Synergy Health plc, a public limited company organized under the laws of England and Wales (“Synergy”). The Combination closed on November 2, 2015 and as a result STERIS plc became the ultimate parent company of Old STERIS and Synergy. Synergy has been re-registered under the name Synergy Health Limited. The acquisition of Old STERIS was accounted for in the consolidated financial statements as a merger between entities under common control; accordingly the historical consolidated financial statements of Old STERIS for periods prior to November 2, 2015, are considered to be the historical financial statements of STERIS plc. Due to the timing of the Combination, the results of Synergy are only reflected in the results of operations of the Company from November 2, 2015, forward will affect the comparability to the prior period historical operations of the Company throughout this Quarterly Report on Form 10-Q. STERIS develops, manufactures and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental Customers throughout the world. As a result of the Combination, we have reorganized our operations into four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. We describe our business segments in note 10 to our consolidated financial statements titled, “Business Segment Information.” Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015 . The Consolidated Balance Sheet at March 31, 2015 was derived from the audited consolidated financial statements at March 31, 2015 , but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. In prior periods we presented income attributable to noncontrolling interests in the "Interest income and miscellaneous expense" line of our Consolidated Statements of Income and the amounts were not material. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2015 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2016 . Recent Accounting Pronouncements Recently issued accounting standards impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2015-16, "Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments" September 2015 The standard requires the recognition of adjustments to provisional amounts, that are identified during the measurement period, in the reporting period in which the adjustments are determined. The effects of the adjustments to provisional amounts on depreciation, amortization or other income effects should be recognized in current-period earnings as if the accounting had been completed at the acquisition date. Disclosure of the portion of the adjustment recorded in current-period earnings that would have been reported in prior reporting periods if the adjustment to the provisional amounts had been recognized at the acquisition date is also required. Third Quarter Fiscal 2016 This update did not have a material impact on our consolidated financial position, results of operations or cash flows. ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs" April 2015 The update requires capitalized debt issuance costs to be presented as a reduction to the carrying value of debt instead of being classified as a deferred charge, as previously required. This update is effective for all annual and interim periods beginning after December 15, 2015 and is required to be adopted retroactively for all periods presented. Early adoption was permitted. First Quarter Fiscal 2016 This update did not have a material impact on our consolidated financial position, results of operations or cash flows. Standards that have not yet been adopted ASU 2014-09, "Revenue from Contracts with Customers" May 2014 The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is not permitted before the original public entity effective date of December 15, 2016. N/A We are currently in the process of evaluating the impact that the standard will have on our consolidated financial position, results of operations and cash flows. ASU 2015-05, "Goodwill and other - Internal-Use Software" (Subtopic 350-40) April 2015 The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted. N/A We are currently in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows. ASU 2015-17, "Income Taxes Balance Sheet Classification of Deferred Taxes" (Topic 740) November 2015 The update will require all entities that present a classified statement of financial position classify all deferred tax liabilities and assets as noncurrent in the statement. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount will not be affected by the Update.The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. N/A We are currently in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in Old STERIS's consolidated financial statements included in its Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015 . Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2015 .

Reclassifications out of AOCI (

Reclassifications out of AOCI (Notes)	9 Months Ended
	Dec. 31, 2015
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2015 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income Three Months Nine Months Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ (332 ) $ 1,068 $ 7,760 $ (8,889 ) $ (66,891 ) $ (58,848 ) $ (59,463 ) $ (66,669 ) Other Comprehensive Income (Loss) before reclassifications (147 ) (1,664 ) (837 ) 32,100 (14,593 ) (22,636 ) (15,577 ) 7,800 Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 158 275 460 (15,828 ) — — 618 (15,553 ) Net current-period Other Comprehensive Income (Loss) 11 (1,389 ) (377 ) 16,272 (14,593 ) (22,636 ) (14,959 ) (7,753 ) Balance at December 31, 2015 $ (321 ) $ (321 ) $ 7,383 $ 7,383 $ (81,484 ) $ (81,484 ) $ (74,422 ) $ (74,422 ) Details of amounts reclassified from Accumulated Other Comprehensive Income (Loss) are as follows: (1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) and settlement of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment	Property, Plant and Equipment Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 38,723 $ 40,668 Buildings and leasehold improvements 440,504 263,007 Machinery and equipment 567,633 375,555 Information systems 121,944 104,049 Radioisotope 431,697 289,778 Linens (2) 41,552 — Construction in progress (1) 87,661 47,690 Total property, plant, and equipment 1,729,714 1,120,747 Less: accumulated depreciation and depletion (676,582 ) (627,694 ) Property, plant, and equipment, net $ 1,053,132 $ 493,053 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service. (2) Linen was acquired as part of our combination with Synergy and is depreciated over useful lives ranging from one to five years. Asset Retirement Obligations We provide contract sterilization services including gamma irradiation which utilizes cobalt-60 in the form of cobalt pencils. We have incurred asset retirement obligations (ARO) associated with the disposal of these depleted assets. Recognition of ARO includes: the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and the periodic review of the ARO liability estimates and discount rates used in the analysis. The following table summarizes the activity in the liability for asset retirement obligations. Asset Retirement Obligations Balance at March 31, 2015 $ 8,083 Liabilities assumed as result of combination with Synergy 8,686 Liabilities incurred during the period 43 Accretion expense 669 Foreign currency movement $ (79 ) Balance at December 31, 2015 $ 17,402

Inventories, Net

Inventories, Net	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Inventories, Net	Inventories, Net Inventories, net are stated at the lower of cost or market. We use the last-in, first-out (“LIFO”) and first-in, first-out cost methods. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: December 31, March 31, Raw materials $ 63,662 $ 67,095 Work in process 20,742 22,696 Finished goods 160,873 107,695 LIFO reserve (17,972 ) (19,071 ) Reserve for excess and obsolete inventory (18,999 ) (17,597 ) Inventories, net $ 208,306 $ 160,818

Debt

Debt	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Debt	Debt Indebtedness was as follows: December 31, March 31, Private Placement $ 662,460 $ 337,825 Credit Agreement 977,001 283,250 Total long term debt $ 1,639,461 $ 621,075 In order to fund the acquisition of Synergy, including the cash payments made in respect of Synergy shares, the repayment of Synergy debt and certain transaction expenses, STERIS plc borrowed (i) $132 million , £49 million , and €127.75 million under the Credit Agreement's revolving credit facility and (ii) $400 million under the Credit Agreement’s term loan facility on November 2, 2015. Borrowings bear interest at the Company’s option based upon either the Base Rate or the Eurocurrency Rate, plus the Applicable Margin in effect from time to time under the Credit Agreement. The Applicable Margin is determined based on the ratio of Consolidated Total Debt to Consolidated EBITDA. Interest on Base Rate Advances is payable quarterly in arrears and interest on Eurocurrency Rate Advances is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months. Additional information regarding our indebtedness is included in the notes to Old STERIS's consolidated financial statements included in Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, dated August 7, 2015, and Annual Report on Form 10-K for the year ended March 31, 2015 , dated May 27, 2015 .

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 35,173 $ 16,680 Accrued vacation/paid time off 13,543 5,539 Accrued bonuses 26,626 30,159 Accrued employee commissions 11,557 12,842 Accrued pension — 6,186 Other postretirement benefit obligations-current portion 2,790 2,789 Other employee benefit plans' obligations-current portion 1,278 610 Total accrued payroll and other related liabilities $ 90,967 $ 74,805 Accrued expenses and other: Deferred revenues $ 42,928 $ 34,910 Self-insured risk reserves-current portion 8,017 6,897 Accrued dealer commissions 14,090 13,591 Accrued warranty 5,504 5,579 Asset retirement obligation-current portion — 1,092 Other 82,128 39,963 Total accrued expenses and other $ 152,667 $ 102,032 Other liabilities: Self-insured risk reserves-long-term portion $ 12,052 $ 12,052 Other postretirement benefit obligations-long-term portion 16,696 18,489 Defined benefit pension plans obligations-long-term portion 23,709 119 Other employee benefit plans obligations-long-term portion 5,570 6,634 Asset retirement obligation-long-term portion 17,402 6,991 Other 9,264 3,049 Total other liabilities $ 84,693 $ 47,334

Income Tax Expense (Benefit)

Income Tax Expense (Benefit)	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Income Tax Expense (Benefit)	Income Tax Expense Income tax expense includes United States federal, state and local, and foreign income taxes, and is based on reported pre-tax income. The effective income tax rates for the three-month periods ended December 31, 2015 and 2014 were 28.1% and 33.0% , respectively. The effective income tax rates for the nine-month periods ended December 31, 2015 and 2014 were 35.6% and 35.5% , respectively. During the first nine months of fiscal 2016 we were unfavorably impacted by acquisition costs. However, this impact was offset by our re-domiciliation in the third quarter and discrete item adjustments. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. As of December 31, 2015, we have reserved for unrecognized tax benefits of $5,521 resulting from our Combination with Synergy. This balance is preliminary and the finalization of this amount may result in upward or downward purchase price allocation. Also at December 31, 2015, we have not recorded any liability for interest and penalties. As of March 31, 2015 we had no unrecognized tax benefits and have not recorded any liability for interest and penalties. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local authorities, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2014 and, with limited exceptions, we are no longer subject to United States state and local or non-United States income tax examinations by tax authorities for years before fiscal 2011. We remain subject to tax authority audits in various jurisdictions wherever we do business. We do not expect the results of these examinations to have a material adverse effect on our consolidated financial statements.

Benefit Plans

Benefit Plans	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Benefit Plans	Benefit Plans In the United States we sponsor an unfunded postretirement welfare benefits plan for two groups of former employees. Benefits under this plan include retiree life insurance and retiree medical coverage, including prescription drug coverage. In July 2014, the Board of Directors of American Sterilizer Company (“AMSCO”) approved the termination of the American Sterilizer Company Retirement Income Plan (“Plan”) effective October 1, 2014. The Pension Benefit Guaranty Corporation ("PBGC") did not object to this termination and AMSCO received a favorable determination from the IRS regarding the termination. On August 19, 2015, an annuity contract was purchased from Massachusetts Mutual Life Insurance Company to provide Plan benefits. Plan assets were converted to cash to fund the purchase. The purchase price of the annuity contract was $51,805 . An additional employer contribution of $4,641 was made to the Plan to fund the annuity purchase obligation on August 26, 2015. As a result the purchase of the annuity, we recognized a pension settlement of $26,470 . In addition, plan benefits and benefit administration became the responsibility of the annuity provider. The assumptions used to measure the benefit obligation as of March 31, 2015 reflected this effort. Additional information regarding this defined benefit pension plan and other postretirement benefits plan is included in our consolidated financial statements included in Old STERIS’s Annual Report on Form 10-K for the year ended March 31, 2015 , dated May 27, 2015 . In addition, as a result of the combination with Synergy, we participate in seven defined benefit pension schemes outside the United States: three in the UK, one in the Netherlands, two in Germany, and one in Switzerland. Preliminarily estimated unfunded obligations of $23,507 were recorded as of the November 2, 2015 closing date of the Combination. In the United Kingdom, we sponsor schemes which are funded defined benefit arrangements. Each has a separate trustee administered fund holding the pension scheme assets to meet long-term pension liabilities for past and present employees. The level of retirement benefit is principally based on the final pensionable salary prior to leaving active service, and is linked to changes in inflation up to retirement. The three UK schemes are as follows: Synergy Health plc Retirement Benefits Scheme: The scheme is a defined benefit (final salary) funded pension scheme. Participation in this scheme is only offered to employees transferring their employment from National Health Service Trusts. Shiloh Group Pension Scheme: The scheme is a defined benefit (final salary) funded pension scheme, which is closed to new members and which ceased accrual of benefits on March 31, 2011. Vernon-Carus Limited Pension and Assurance Scheme: The scheme is a defined benefit (final salary) funded pension scheme, which is closed to new members and which ceased accrual of benefits on March 31, 2011. In previous years, Synergy sponsored a funded defined benefit arrangement in the Netherlands. This was a separate fund holding the pension scheme assets to meet long term pension liabilities for past and present employees. Accrual of benefits ceased under the scheme effective January 1, 2013. The Synergy Radeberg and Synergy Alleshausen Schemes are German defined benefit funded pension schemes which are closed to new entrants. The Synergy Daniken Scheme is a Swiss defined benefit funded pension scheme. Components of the net periodic benefit cost for our defined benefit pension plans and other postretirement medical benefits plan were as follows: AMSCO Plan Other Defined Benefit Pension Plans Other Postretirement Benefits Plan Three Months Ended December 31, 2015 2014 2015 2014 2015 2014 Service cost $ — $ 35 $ 324 $ — $ — $ — Interest cost — 471 641 — 148 173 Expected return on plan assets — (785 ) (506 ) — — — Amortization of loss — 277 — — 207 180 Settlement — — — — — — Amortization of prior service cost — — — — (815 ) (816 ) Net periodic benefit cost $ — $ (2 ) $ 459 $ — $ (460 ) $ (463 ) AMSCO Plan Other Defined Benefit Pension Plans Other Postretirement Benefits Plan Nine Months Ended December 31, 2015 2014 2015 2014 2015 2014 Service cost $ 27 $ 105 $ 324 — — — Interest cost 560 1,415 641 — 444 518 Expected return on plan assets (1,008 ) (2,355 ) (506 ) — — — Amortization of loss 602 830 — — 621 541 Settlement 26,515 — — — — — Amortization of prior service cost — — — — (2,445 ) (2,447 ) Net periodic benefit cost $ 26,696 $ (5 ) $ 459 $ — $ (1,380 ) $ (1,388 ) We contribute amounts to the defined benefit pension plans at least sufficient to meet the minimum requirements as stated in applicable employee benefit laws and local tax laws. The United Kingdom schemes are subject to the funding legislation outlined in the Pensions Act 2004 of the United Kingdom. This, together with documents issued by the UK Pensions Regulator, and Guidance Notes adopted by the Financial Reporting Council, set out the framework for funding defined benefit occupational pension schemes in the United Kingdom. The trustees of the schemes are required to act in the best interest of the schemes’ beneficiaries. The appointment of the trustees is determined by the schemes’ trust documentation. We record liabilities for the difference between the fair value of the plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated postretirement benefit obligation for other postretirement benefits plans) on our accompanying condensed Consolidated Balance Sheets. Finally, the Dutch linen business acquired in the Synergy combination participates in a multi-employer industry-wide defined benefit scheme. Participation in this pension plan is mandatory. The pension scheme is an average pay scheme with a conditional fee (indexation). Indexation of the assets and liabilities granted under the pension scheme takes place only if and insofar as the resources of the fund allow for it and this decision is taken by the pension fund. The pension entitlements under the pension plan are fully reinsured. It is not possible to identify the share of the underlying assets, liabilities, and overall surplus/deficit of the scheme attributable to the business, because the scheme is industry-wide. Under the guidance provided in ASC 715, "Compensation-Retirement Benefits", the scheme is treated as a defined contribution scheme within our financial statements. The total cost charged to the income statement in respect of this scheme was $459 for the three-month and nine-month periods ended December 31, 2015 .

Contingencies

Contingencies	9 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Contingency [Text Block]	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results. On December 19, 2014, a purported shareholder of Old STERIS filed a Verified Stockholder Derivative Complaint in the Court of Common Pleas, Cuyahoga County, Ohio (the “Court”), against the members of Old STERIS’s board of directors and certain officers of Old STERIS, challenging the excise tax make-whole payments approved by Old STERIS’s board of directors in connection with the Combination. Old STERIS was named as a nominal defendant in the action. The case is captioned St. Lucie County Fire District Firefighters’ Pension Trust Fund v. Rosebrough, Jr., et al., Case No. CV 14 837749 (the “Action”). On September 28, 2015, the defendants reached an agreement in principle with plaintiff, regarding a settlement of the Action, and that agreement is reflected in a memorandum of understanding. In connection with the contemplated settlement, Old STERIS agreed to make certain additional disclosures related to the make-whole payments, which disclosures were reported on Old STERIS’s Form 8-K dated September 28, 2015, and also agreed not to grant any new stock compensation subject to Section 4985 of the Internal Revenue Code to any of the individual defendants in the Action until six months following the closing date of the Combination. The memorandum of understanding contemplates that the parties will enter into a stipulation of settlement, which will be subject to customary conditions, including the approval of the Court. In addition, in connection with the settlement, the parties have agreed to negotiate in good faith regarding the amount of attorneys’ fees and expenses that shall be paid to plaintiff’s counsel in connection with the Action. There can be no assurance that the parties will ultimately enter into a stipulation of settlement or that the Court will approve any stipulation of settlement. In such event, the proposed settlement as contemplated by the memorandum of understanding may be terminated. On July 8, 2015, the United States District Court for the Northern District of Ohio issued an Order terminating the April 20, 2010 consent decree entered into by two Company employees and the United States. The consent decree related to U.S. Food and Drug Administration (FDA) allegations regarding the Company’s now discontinued SYSTEM 1 ® liquid chemical sterilization system. As a result of the termination of the consent decree, the Company is no longer subject to any court order related to its FDA regulatory compliance. Other civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015: “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factor” titled “We may be adversely affected by product liability claims or other legal actions or regulatory or compliance matters, including the Consent Decree”. From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of the applicable statute of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. Additional information regarding our contingencies is included in Item 7 of Part II titled, “Management's Discussion and Analysis of Financial Conditions and Results of Operations,” of Old STERIS’s Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015, and in Item 1 of Part II of this Form 10-Q titled, “Legal Proceedings.”

Business Segment Information

Business Segment Information	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Business Segment Information	Business Segment Information As a result of the Combination with Synergy, we have reassessed the organization of our business. We have concluded that we operate and report in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs. Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables. Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. Our Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. Our Applied Sterilization Technologies segment offers a contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The accounting policies for reportable segments are the same as those for the consolidated Company. Management evaluates performance and allocates resources based on a segment operating income measure. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which result in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare Products segment is responsible for the management of all but two manufacturing facilities and uses standard cost to sell products to the other segments. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits. Segment operating income excludes certain adjustments which include acquisition related costs, amortization of acquired intangibles, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by excluding these items they gain better insight and greater transparency of the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making. For the three and nine month periods ended December 31, 2015 , revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in Old STERIS's consolidated financial statements included in its Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015 . Financial information for each of our reportable segments is presented in the following tables: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Revenues: Healthcare Products $ 317,060 $ 287,515 $ 872,028 $ 823,957 Healthcare Specialty Services 128,326 65,682 264,974 183,219 Life Sciences 82,702 67,997 210,514 185,759 Applied Sterilization Technologies 90,225 50,960 199,753 154,003 Corporate and other 375 1,090 1,218 1,678 Total revenues $ 618,688 $ 473,244 $ 1,548,487 $ 1,348,616 Segment operating income: Healthcare Products $ 52,141 $ 42,720 $ 120,674 $ 109,766 Healthcare Specialty Services 7,389 5,195 17,620 11,074 Life Sciences 24,115 16,482 58,448 41,615 Applied Sterilization Technologies 26,766 14,006 60,802 44,792 Corporate and other (2,648 ) (1,406 ) (8,580 ) (5,310 ) Total segment operating income $ 107,763 $ 76,997 $ 248,964 $ 201,937 Less: Adjustments Restructuring charges (1) $ (193 ) $ (1,076 ) $ (657 ) $ (427 ) Amortization of acquired intangible assets (2) 15,494 5,845 28,194 22,563 Acquisition and integration related charges (3) 41,726 10,860 77,254 17,556 Amortization of inventory and property "step up" to fair value (2) 4,060 22 4,102 1,310 Settlement of pension obligation (4) (46 ) — 26,470 — Loss on fair value of contingent consideration — — — 1,998 Total operating income $ 46,722 $ 61,346 $ 113,601 $ 158,937 (1) See Note 2 titled, "Restructuring" for more information related to restructuring. (2) For more information regarding our recent acquisitions see Note 18 titled, "Business Acquisitions", as well as Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015 , dated May 27, 2015 . (3) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (4) See Note 8 titled, "Benefit Plans" for more information related to the settlement of the pension obligation. Individual facilities, equipment, and intellectual properties are utilized for production by the Healthcare Products and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of these segments. Therefore, their respective amounts are reported together. December 31, 2015 March 31, 2015 Assets: Healthcare Products and Life Sciences $ 1,684,872 $ 1,261,940 Healthcare Specialty Services 753,396 396,579 Applied Sterilization Technologies 1,488,295 436,638 Total reportable segments 3,926,563 2,095,157 Corporate and other 2,521 2,134 Synergy related goodwill not yet allocated (1) 1,421,199 — Total assets $ 5,350,283 $ 2,097,291 (1) Amount is still preliminary as of December 31, 2015, as valuations have not been finalized. Goodwill will be allocated to the Healthcare Products, Healthcare Specialty Services and Applied Sterilization Technologies business segments. Nine months ended, December 31, 2015 December 31, 2014 Capital Expenditures: Healthcare Products and Life Sciences $ 22,120 $ 20,626 Healthcare Specialty Services 17,533 1,386 Applied Sterilization Technologies 42,457 34,731 Total Reportable Segments 82,110 56,743 Corporate and other 7 14 Total Capital Expenditures $ 82,117 $ 56,757 Depreciation, Depletion, and Amortization: Healthcare Products and Life Sciences $ 34,728 $ 30,900 Healthcare Specialty Services 20,142 15,961 Applied Sterilization Technologies 35,999 22,552 Total Reportable Segments 90,869 69,413 Corporate and other 56 27 Total Depreciation, Depletion, and Amortization $ 90,925 $ 69,440 Financial information for the United Kingdom, United States and other international countries is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant and equipment, net are those assets that are identified within the operations in each country or area. Three months ended December 31, Nine months ended December 31, 2015 2014 2015 2014 Revenues: United Kingdom $ 51,468 $ 13,421 $ 73,382 $ 38,225 United States 438,250 367,059 1,193,940 1,049,892 Other International 128,970 92,764 281,165 260,499 Total Revenues $ 618,688 $ 473,244 $ 1,548,487 $ 1,348,616 December 31, 2015 March 31, 2015 2015 2015 Property, Plant, and Equipment, Net United Kingdom $ 121,876 $ 12,816 United States 506,916 441,278 Other International 424,340 38,959 Property, Plant, and Equipment, Net $ 1,053,132 $ 493,053

Shares and Preferred Shares

Shares and Preferred Shares	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Earnings Per Share [Text Block]	11. Shares and Preferred Shares Common and Ordinary Shares In connection with the Combination, each Old STERIS common shareholder received one ordinary share, par value 10 pence, of the Company for each Old STERIS common share held, and each Synergy ordinary shareholder received 0.4308 ordinary shares, par value 10 pence, of the Company and 439 pence in cash, for each Synergy ordinary share held. We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Denominator (shares in thousands): Weighted average shares outstanding—basic 77,221 59,475 65,629 59,340 Dilutive effect of share equivalents 491 671 494 653 Weighted average shares outstanding and share equivalents—diluted 77,712 60,146 66,123 59,993 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 (shares in thousands) Number of share options 293 268 254 367 Preferred Shares Pursuant to an engagement letter dated October 23, 2015, we issued 100,000 preferred shares, par value of £0.10 ( $0.15 ) each, for an aggregate consideration of £10,000 or approximately $15 , in satisfaction of debt owed to a service provider. The holders of the preferred shares are entitled to a fixed cumulative preferential annual dividend of 5 percent on the amount paid periodically on the preferred shares respectively held by them. On a return of capital of the Company whether on liquidation or otherwise, the holders of the preferred shares shall be entitled to receive out of the assets of the Company available for distribution to its shareholders the sum of £0.10 ( $0.15 ) per preferred share plus any accrued but unpaid dividend, but will not be entitled to any further participation in the assets of the Company. The holders of the preferred shares will have no right to attend, speak or vote, whether in person or by proxy, at any general meeting of the Company or any meeting of a class of members of the Company in respect of the preferred shares and will not be entitled to receive any notice of meetings.

Repurchases of Common Shares

Repurchases of Common Shares	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Schedule of Treasury Stock by Class [Text Block]	Repurchases of Shares During the first nine months of fiscal 2016, we obtained 215,164 of our shares in connection with stock based compensation award programs.

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation We maintain a long-term incentive plan which we assumed from Old STERIS, that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. Prior to the Combination, awards were made in respect of common shares of Old STERIS. In conjunction with the Combination all outstanding common share denominated awards were converted into an equivalent number of Company ordinary share denominated awards, with the same terms and conditions as applied to the replaced awards. Stock options provide the right to purchase our shares at the market price on the date of grant, subject to the terms of the option plans and agreements. Generally, one-fourth of the stock options granted become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally may cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each full year of employment after the grant date. As of December 31, 2015 , 2,202,425 shares remained available for grant under the long-term incentive plan. The fair value of share-based compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2016 and fiscal 2015 : Fiscal 2016 Fiscal 2015 Risk-free interest rate 1.51 % 1.89% Expected life of options 5.69 years 5.75 years Expected dividend yield of stock 1.40 % 1.87% Expected volatility of stock 25.06 % 29.86% The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of our historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 1.55% and 1.46% was applied in fiscal 2016 and 2015 , respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2015 1,759,890 $ 37.03 Granted 366,700 66.88 Exercised (337,982 ) 32.25 Forfeited (37,461 ) 54.61 Canceled (500 ) 24.45 Outstanding at December 31, 2015 1,750,647 $ 43.83 6.5 years $ 55,160 Exercisable at December 31, 2015 997,531 $ 34.34 4.9 years $ 40,902 We estimate that 741,954 of the non-vested stock options outstanding at December 31, 2015 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $75.34 closing price of our ordinary shares on December 31, 2015 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our ordinary shares. The total intrinsic value of stock options exercised during the first nine months of fiscal 2016 and fiscal 2015 was $12,221 and $22,289 , respectively. Net cash proceeds from the exercise of stock options were $10,908 and $19,245 for the first nine months of fiscal 2016 and fiscal 2015 , respectively. The tax benefit from shared-based compensation was $5,909 and $8,880 for the first nine months of fiscal 2016 and fiscal 2015 , respectively. The weighted average grant date fair value of stock option grants was $14.66 and $13.41 for the first nine months of fiscal 2016 and fiscal 2015 , respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of December 31, 2015 and 2014 was $2,527 and $2,073 , respectively. A summary of the non-vested restricted share activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2015 851,173 32,800 $ 42.98 Granted 277,483 22,405 68.16 Vested (205,453 ) (12,071 ) 39.73 Canceled (44,821 ) (1,493 ) 49.84 Non-vested at December 31, 2015 878,382 41,641 $ 51.61 Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares that vested during the first nine months of fiscal 2016 was $7,913 . Restricted share units carry generally the same terms and vesting requirements as restricted stock except that they may be settled in stock or cash upon vesting. Those that are settled in cash are classified as liabilities. All outstanding cash-settled restricted share units vested in the first quarter of fiscal 2016 and the only remaining outstanding restricted stock units are stock settled. The fair value of outstanding cash-settled restricted share units as of March 31, 2015 was $334 . The fair value of each cash-settled restricted share unit is revalued at each reporting date and the related liability and expense are adjusted appropriately. As of December 31, 2015 , there was a total of $36,581 in unrecognized compensation cost related to nonvested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.3 years .

Financial and Other Guarantees

Financial and Other Guarantees	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Product Warranty Disclosure [Text Block]	Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first nine months of fiscal 2016 were as follows: Balance, March 31, 2015 $ 5,579 Warranties issued during the period 8,063 Settlements made during the period (8,138 ) Balance, December 31, 2015 $ 5,504 We also sell product maintenance contracts to our Customers. These contracts range in terms from one to five years and require us to maintain and repair the product over the maintenance contract term. We initially record amounts due from Customers under these contracts as a liability for deferred service contract revenue on the accompanying Consolidated Balance Sheets within “Accrued expenses and other.” The liability recorded for such deferred service revenue was $31,687 and $30,720 as of December 31, 2015 and March 31, 2015 , respectively. Such deferred revenue is then amortized on a straight-line basis over the contract term and recognized as service revenue on our accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenues is excluded from the table presented above.

Derivatives and Hedging

Derivatives and Hedging	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2015 , we held foreign currency forward contracts to buy 9 million Canadian dollars, 90 million Mexican pesos, and 4.5 million British pounds sterling. At December 31, 2015 , we held commodity swap contracts to buy 181.2 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance Sheet Location December 31, 2015 March 31, 2015 December 31, 2015 March 31, 2015 Prepaid & Other $ — $ 12 $ — $ — Accrued expenses and other $ — $ — $ 759 $ 616 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Foreign currency forward contracts Selling, general and administrative $ (380 ) $ (513 ) $ (642 ) $ (660 ) Commodity swap contracts Cost of revenues $ (159 ) $ (100 ) $ (491 ) $ 214 Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $135,121 at December 31, 2015. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Fair Value Disclosures [Text Block]	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at December 31, 2015 and March 31, 2015: Fair Value Measurements at December 31, 2015 and March 31, 2015 Using Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 December 31 March 31 December 31 March 31 December 31 March 31 December 31 March 31 Assets: Cash and cash equivalents (1) $ 231,360 $ 167,689 $ 207,525 $ 148,944 $ 23,835 $ 18,745 $ — $ — Forward and swap contracts (2) — 12 — — — 12 — — Investments (3) 7,579 8,332 7,579 8,332 — — — — Liabilities: Forward and swap contracts (2) $ 759 $ 616 $ — $ — $ 759 $ 616 $ — $ — Deferred compensation plans (3) 2,707 3,757 2,707 3,757 — — — — Long term debt (4) 1,639,461 621,075 — — 1,642,034 641,131 — — Contingent consideration obligations (5) 4,557 2,500 — — — — 4,557 2,500 (1) Money market fund holdings are classified as level two as active market quoted prices are not available. (2) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (3) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment. (4) We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (5) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2015 are summarized as follows: Contingent Consideration Balance at March 31, 2015 $ 2,500 Liabilities assumed as result of combination with Synergy 1,561 Additions 800 Payments (122 ) Foreign currency translation adjustments (1) (182 ) Balance at December 31, 2015 $ 4,557 (1) Reported in other comprehensive income (loss) . Information regarding our investments is as follows: Investments at December 31, 2015 and March 31, 2015 Cost Unrealized Gains Unrealized Losses (2) Fair Value December 31 March 31 December 31 March 31 December 31 March 31 December 31 March 31 Available-for-sale securities: Marketable equity securities (1) $ 4,681 $ 4,681 $ 252 $ — $ — $ — $ 4,933 $ 4,681 Mutual funds 1,994 2,677 652 974 — — 2,646 3,651 Total available-for-sale securities $ 6,675 $ 7,358 $ 904 $ 974 $ — $ — $ 7,579 $ 8,332 (1) Our marketable equity securities have been in a unrealized loss position for less than 12 months. (2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Restructuring (Notes)

Restructuring (Notes)	9 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring Fiscal 2014 Restructuring Plan. During the fourth quarter of fiscal 2014, Old STERIS adopted and announced a targeted restructuring plan primarily focused on the closure of its Hopkins manufacturing facility located in Mentor, Ohio (the “Fiscal 2014 Restructuring Plan”). As a result of this plan, operations located at Hopkins were transfered to other North American locations. We believe that by closing the operations at Hopkins we will more effectively utilize our existing North American manufacturing network while reducing operating costs. Since the inception of the Fiscal 2014 Restructuring Plan, we have incurred pre-tax expenses totaling $18,815 related to these actions, of which $10,720 was recorded as restructuring expenses and $8,095 was recorded in cost of revenues.We do not expect to incur any significant additional restructuring expenses related to this plan. These actions are intended to enhance profitability and improve efficiencies. Our total pre-tax restructuring expenses (credits) for the third quarter and first nine months of fiscal 2016 were ($193) and ($657) , respectively. Our total pre-tax restructuring expenses (credits) for the third quarter and first nine months of fiscal 2015 were ($1,076) and ($427) , respectively. Liabilities related to restructuring activities were $1,085 and $2,887 at December 31, 2015 and March 31, 2015, respectively. They are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.”

Business Acquisitions (Notes)

Business Acquisitions (Notes)	9 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Business Acquisitions Synergy Health plc On November 2, 2015, STERIS acquired all outstanding shares of Synergy in a cash and stock transaction valued at £24.80 ( $38.17 ) per Synergy share, or a total of approximately $2.3 billion based on the low trading price of Old STERIS’s stock of $73.02 per share on November 2, 2015. The Combination brings together businesses that will generate revenues from over 60 countries, employ approximately 14,000 employees, and are geographically complementary. The Combination is expected to result in cost savings from optimizing global back-office infrastructure, leveraging best-demonstrated practices across plants, in-sourcing consumables, and eliminating redundant public company costs. Total costs of approximately $63,174 before tax, were incurred during the first nine months of fiscal year 2016 related to the Combination and are reported in selling, general and administrative expense. Total consideration for the transaction is presented in the table below. At the closing date, vested share option awards remained outstanding under Synergy's Save As You Earn Plans ("SAYE"). In accordance with the provisions of SAYE, vested option awards may be exercised to the extent that the exercise price funds have been accumulated in accordance with the option holder's savings contract. The number of Synergy shares that are expected to be issued have been estimated and have been fair valued based on the same cash and stock consideration available to other Synergy shareholders at the time of the Combination. Cash consideration $ 402,494 STERIS plc shares (25,848,798 ordinary shares estimated to be issued) 1,887,479 Fair value of consideration available to vested Synergy share option holders 3,626 Total purchase consideration $ 2,293,599 The acquisition of Synergy has been accounted for using the acquisition method of accounting which requires, among other things, the assets acquired and liabilities assumed be recognized at their respective fair values as of the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates. The entire purchase price allocation for Synergy is preliminary. As we finalize the fair value of assets acquired and liabilities assumed, additional purchase price adjustments will be recorded during the measurement period. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. The finalization of the purchase accounting assessment will result in changes in the valuation of assets acquired and liabilities assumed and may have a material impact on the our results of operations and financial position. Goodwill will be allocated to the Healthcare Products, Healthcare Specialty Services, and Applied Sterilization Technologies segments. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce, which are further described above. Goodwill recognized as a result of the acquisition is not deductible for tax purposes. Other Fiscal 2016 Acquisitions On July 31, 2015 we acquired all of the outstanding shares of General Econopak, Inc. (“Gepco”) for a purchase price of $176,260 in cash, subject to a customary working capital adjustment. Gepco is a Pennsylvania-based manufacturer of product solutions in the areas of sterility maintenance, barrier protection, and sterile cleanroom products for pharmaceutical, biotechnology and veterinary Customers. Gepco is being integrated into our Life Sciences business segment. The purchase price was financed through a combination of credit facility borrowings and cash on hand. The allocation of premium to intangibles and goodwill is preliminary and will be finalized after the valuation reports are completed. We anticipate that the acquisition will qualify for joint election tax benefit under Section 338 (h)(10) of the Internal Revenue Code. We recorded $2,379 of acquisition related costs, which are reported in selling, general and administrative expense. On June 12, 2015 we acquired the capital stock of Black Diamond Video, Inc. ("Black Diamond"), a California-based developer and provider of operating room integration systems. The purchase price was approximately $46,766 , which includes deferred consideration of $5,870 , to be paid approximately twelve months after the closing date, and contingent consideration of $800 , and is subject to a working capital adjustment. The transaction consideration paid at closing was funded with cash on hand. Black Diamond is being integrated into our Healthcare Products business segment. The allocation of premium to intangibles and goodwill is preliminary and will be finalized after the valuation reports are completed. We also completed several other minor purchases that continued to expand our service offerings in the Healthcare Products, Healthcare Specialty Services and Life Sciences segments. The aggregate purchase price associated with these transactions was approximately $41,344 , including potential contingent consideration of $1,760 . The Consolidated Financial Statements include the operating results of these fiscal 2016 acquisitions from the acquisition dates. Pro-forma results of operations for the fiscal 2015 periods have not been presented because the effects of the acquisition were not material to our financial results. Acquisition related costs associated with fiscal 2016 acquisitions with the exception of Synergy and Gepco, have not been significant. Fair Value of Assets Acquired and Liabilities Assumed The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date. These preliminary estimates will be revised during the measurement period as third-party valuations are finalized, additional information becomes available and as additional analyzes are performed, and these differences could have a material impact on our results of operations and financial position. Synergy (1) Gepco (1) Black Diamond (1) Other Acquisitions Cash $ 53,057 $ 1,108 $ — $ — Accounts receivable 104,666 4,161 2,966 3,859 Inventory 30,074 1,926 3,309 1,108 Property, plant and equipment 534,879 946 607 1,979 Other assets 19,708 1,621 43 — Intangible assets 806,526 67,189 13,500 13,631 Goodwill 1,415,274 100,782 36,654 22,093 Total assets acquired 2,964,184 177,733 57,079 42,670 Current liabilities (110,727 ) (1,473 ) (4,525 ) (1,277 ) Long-term indebtedness (321,082 ) — — — Other non-current liabilities (230,020 ) — (5,788 ) (49 ) Total liabilities assumed (661,829 ) (1,473 ) (10,313 ) (1,326 ) Net assets acquired $ 2,302,355 $ 176,260 $ 46,766 $ 41,344 (1) Purchase price allocation is still preliminary as of December 31, 2015, as valuations have not been finalized . Intangible assets acquired in the Synergy acquisition consist of trade names, technology and Customer relationships. Preliminary values and useful lives are presented in the table below. Total (1) Useful Live Customer relationships $ 717,254 10-17 years Trade names 64,645 10 years Technology 24,627 7 years Total intangible assets acquired $ 806,526 (1) Amounts are preliminary as of December 31, 2015, as valuations have not been finalized. Contingent liabilities assumed as part of the Combination total $7,082 and are included within accrued expenses and other and other liabilities in the condensed consolidated balance sheet. These contingent liabilities include $5,521 related to income taxes (including uncertain tax positions) and $1,561 related to contingent consideration associated with prior acquisitions completed by Synergy. Contingent liabilities are recorded at their estimated fair values, aside from those pertaining to uncertainty in income taxes which are an exception to the fair value basis of accounting. See note 16, titled "Fair Value Measurements" to the condensed consolidated financial statements for additional information on contingent liabilities. The estimated fair values noted above are preliminary and are subject to change upon finalization of the purchase accounting assessment and may have a material impact on the our results of operations and financial position. Actual and Pro Forma Impact Our consolidated financial statements include Synergy's results of operations from the date of acquisition on November 2, 2015 through December 31, 2015. Net sales and operating income (loss) attributable to Synergy during this period and included in our consolidated financial statements for the three and nine month periods ended December 31, 2015 total $103,052 and $(1,659) , respectively. The following unaudited pro forma information gives effect to our acquisition of Synergy as if the acquisition had occurred on April 1, 2014 and Synergy had been included in our consolidated results of operations for the three and nine month periods ended December 31, 2015 and December 31, 2014. Three Months Ended December 31, Nine Months Ended December 31, (unaudited) (unaudited) 2015 2014 2015 2014 Net revenues $ 681,254 $ 638,857 $ 1,928,779 $ 1,831,740 Net income from continuing operations 45,910 39,406 118,388 111,046 The historical consolidated financial information of STERIS and Synergy has been adjusted in the pro forma information to give effect to pro forma events that are (1) directly attributable to the transaction, (2) factually supportable and (3) expected to have a continuing impact on the combined results. In order to reflect the occurrence of the acquisition on April 1, 2014 as required, the unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up, the incremental depreciation from the fair value adjustments to property, plant and equipment, and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets acquired. Adjustments to financing costs and income tax expense also were made to reflect the capital structure and anticipated effective tax rate of the combined entity. These pro forma amounts are not necessarily indicative of the results that would have been obtained if the acquisition had occurred as of the beginning of the period presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings.

Related Party Transactions (Not

Related Party Transactions (Notes)	9 Months Ended
	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Related Party Transactions Disclosure [Text Block]	19. Related Party Transactions On October 26, 2015, in connection with the consummation of the Combination, Dr. Richard Steeves, Group Executive Officer and Director of Synergy, elected to exercise employee stock options and hold the resulting Synergy shares. This exercise created an obligation on the part of Dr. Steeves totaling £3.1 million for income taxes and United Kingdom National Insurance contributions to be remitted by Synergy on his behalf, as well as the option exercise price. Synergy’s past practice, when requested by the employee who elected to exercise stock options and hold the resulting shares, was to pay income taxes and U.K. National Insurance contributions when due and obtain reimbursement from the employee for such taxes and the option exercise price within 90 days from the date of remittance. Upon completion of the Combination on November 2, 2015, Dr. Steeves ceased to be the Group Executive Officer and a Director of Synergy and became a non-executive Director of STERIS plc. Pursuant to the terms of the Combination, Dr. Steeves received STERIS plc shares and cash proceeds on November 6, 2015 in exchange for his Synergy equity holdings. The amount of the cash proceeds was £1.25 million , which was retained by Synergy and applied to his obligation, thereby reducing it to £1.86 million . Synergy remitted the £3.1 million of income taxes and U.K. National Insurance contributions to the appropriate United Kingdom agencies on November 20, 2015. Dr. Steeves remitted the balance of £1.86 million to Synergy on January 27, 2016 in satisfaction of his obligation to reimburse Synergy for the sums remitted by Synergy on his behalf. The arrangement between Dr. Steeves and Synergy effectively created a receivable that, under U.S. GAAP, was considered a loan. Loans by a public company to its executive officers and directors are prohibited under the Sarbanes-Oxley Act of 2002 and are also prohibited by the Company’s corporate governance policies and procedures. STERIS Corporation was not aware at the time of the closing of the Combination that Synergy had agreed to defer to a later date Dr. Steeves's obligation to reimburse the income taxes and U.K. National Insurance contributions and the option exercise price. Senior management learned of the arrangement when it was identified in the Company’s quarterly internal controls processes. Prepaid expenses and other current assets in the Company’s consolidated balance sheet includes the amount outstanding from Dr. Steeves, as well as a further amount due from another Synergy employee who also elected to exercise and hold Synergy shares immediately prior to the completion of the Combination. The other employee is neither an executive officer nor director of the Company. This additional amount was $368 , which resulted in total receivables for both option exercises of $5,152 and $3,117 as of the November 2, 2015 acquisition date and December 31, 2015, respectively. The December 31, 2015 balances were remitted to Synergy in January 2016 and as a result of the repayments, no such amounts remain outstanding.

Nature of Operations and Summ26

Nature of Operations and Summary of Significant Accounting Policies Policies (Policies)	9 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. In prior periods we presented income attributable to noncontrolling interests in the "Interest income and miscellaneous expense" line of our Consolidated Statements of Income and the amounts were not material.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2015 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2016 .
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recently issued accounting standards impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2015-16, "Business Combinations - Simplifying the Accounting for Measurement-Period Adjustments" September 2015 The standard requires the recognition of adjustments to provisional amounts, that are identified during the measurement period, in the reporting period in which the adjustments are determined. The effects of the adjustments to provisional amounts on depreciation, amortization or other income effects should be recognized in current-period earnings as if the accounting had been completed at the acquisition date. Disclosure of the portion of the adjustment recorded in current-period earnings that would have been reported in prior reporting periods if the adjustment to the provisional amounts had been recognized at the acquisition date is also required. Third Quarter Fiscal 2016 This update did not have a material impact on our consolidated financial position, results of operations or cash flows. ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs" April 2015 The update requires capitalized debt issuance costs to be presented as a reduction to the carrying value of debt instead of being classified as a deferred charge, as previously required. This update is effective for all annual and interim periods beginning after December 15, 2015 and is required to be adopted retroactively for all periods presented. Early adoption was permitted. First Quarter Fiscal 2016 This update did not have a material impact on our consolidated financial position, results of operations or cash flows. Standards that have not yet been adopted ASU 2014-09, "Revenue from Contracts with Customers" May 2014 The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is not permitted before the original public entity effective date of December 15, 2016. N/A We are currently in the process of evaluating the impact that the standard will have on our consolidated financial position, results of operations and cash flows. ASU 2015-05, "Goodwill and other - Internal-Use Software" (Subtopic 350-40) April 2015 The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted. N/A We are currently in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows. ASU 2015-17, "Income Taxes Balance Sheet Classification of Deferred Taxes" (Topic 740) November 2015 The update will require all entities that present a classified statement of financial position classify all deferred tax liabilities and assets as noncurrent in the statement. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount will not be affected by the Update.The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted. N/A We are currently in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.

Reclassifications out of AOCI27

Reclassifications out of AOCI (Tables)	9 Months Ended
	Dec. 31, 2015
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2015 were as follows: Gain (Loss) on Available for Sale Securities (1) Defined Benefit Plans (2) Foreign Currency Translation (3) Total Accumulated Other Comprehensive Income Three Months Nine Months Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ (332 ) $ 1,068 $ 7,760 $ (8,889 ) $ (66,891 ) $ (58,848 ) $ (59,463 ) $ (66,669 ) Other Comprehensive Income (Loss) before reclassifications (147 ) (1,664 ) (837 ) 32,100 (14,593 ) (22,636 ) (15,577 ) 7,800 Amounts reclassified from Accumulated Other Comprehensive Income (Loss) 158 275 460 (15,828 ) — — 618 (15,553 ) Net current-period Other Comprehensive Income (Loss) 11 (1,389 ) (377 ) 16,272 (14,593 ) (22,636 ) (14,959 ) (7,753 ) Balance at December 31, 2015 $ (321 ) $ (321 ) $ 7,383 $ 7,383 $ (81,484 ) $ (81,484 ) $ (74,422 ) $ (74,422 ) Details of amounts reclassified from Accumulated Other Comprehensive Income (Loss) are as follows: (1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income. (2) Amortization (gain) and settlement of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Property, Plant and Equipment L

Property, Plant and Equipment Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Property, Plant and Equipment [Table Text Block]	Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 38,723 $ 40,668 Buildings and leasehold improvements 440,504 263,007 Machinery and equipment 567,633 375,555 Information systems 121,944 104,049 Radioisotope 431,697 289,778 Linens (2) 41,552 — Construction in progress (1) 87,661 47,690 Total property, plant, and equipment 1,729,714 1,120,747 Less: accumulated depreciation and depletion (676,582 ) (627,694 ) Property, plant, and equipment, net $ 1,053,132 $ 493,053 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service. (2) Linen was acquired as part of our combination with Synergy and is depreciated over useful lives ranging from one to five years.
Asset Retirement Obligations [Table Text Block]	Asset Retirement Obligations Balance at March 31, 2015 $ 8,083 Liabilities assumed as result of combination with Synergy 8,686 Liabilities incurred during the period 43 Accretion expense 669 Foreign currency movement $ (79 ) Balance at December 31, 2015 $ 17,402

Inventories, Net Level 3 (Table

Inventories, Net Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: December 31, March 31, Raw materials $ 63,662 $ 67,095 Work in process 20,742 22,696 Finished goods 160,873 107,695 LIFO reserve (17,972 ) (19,071 ) Reserve for excess and obsolete inventory (18,999 ) (17,597 ) Inventories, net $ 208,306 $ 160,818

Debt Level 3 (Tables)

Debt Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Schedule of Debt [Table Text Block]	Indebtedness was as follows: December 31, March 31, Private Placement $ 662,460 $ 337,825 Credit Agreement 977,001 283,250 Total long term debt $ 1,639,461 $ 621,075

Additional Consolidated Balan31

Additional Consolidated Balance Sheets Information Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 35,173 $ 16,680 Accrued vacation/paid time off 13,543 5,539 Accrued bonuses 26,626 30,159 Accrued employee commissions 11,557 12,842 Accrued pension — 6,186 Other postretirement benefit obligations-current portion 2,790 2,789 Other employee benefit plans' obligations-current portion 1,278 610 Total accrued payroll and other related liabilities $ 90,967 $ 74,805 Accrued expenses and other: Deferred revenues $ 42,928 $ 34,910 Self-insured risk reserves-current portion 8,017 6,897 Accrued dealer commissions 14,090 13,591 Accrued warranty 5,504 5,579 Asset retirement obligation-current portion — 1,092 Other 82,128 39,963 Total accrued expenses and other $ 152,667 $ 102,032 Other liabilities: Self-insured risk reserves-long-term portion $ 12,052 $ 12,052 Other postretirement benefit obligations-long-term portion 16,696 18,489 Defined benefit pension plans obligations-long-term portion 23,709 119 Other employee benefit plans obligations-long-term portion 5,570 6,634 Asset retirement obligation-long-term portion 17,402 6,991 Other 9,264 3,049 Total other liabilities $ 84,693 $ 47,334

Benefit Plans Level 3 (Tables)

Benefit Plans Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Schedule of Defined Benefit Plans Disclosures [Table Text Block]	Components of the net periodic benefit cost for our defined benefit pension plans and other postretirement medical benefits plan were as follows: AMSCO Plan Other Defined Benefit Pension Plans Other Postretirement Benefits Plan Three Months Ended December 31, 2015 2014 2015 2014 2015 2014 Service cost $ — $ 35 $ 324 $ — $ — $ — Interest cost — 471 641 — 148 173 Expected return on plan assets — (785 ) (506 ) — — — Amortization of loss — 277 — — 207 180 Settlement — — — — — — Amortization of prior service cost — — — — (815 ) (816 ) Net periodic benefit cost $ — $ (2 ) $ 459 $ — $ (460 ) $ (463 ) AMSCO Plan Other Defined Benefit Pension Plans Other Postretirement Benefits Plan Nine Months Ended December 31, 2015 2014 2015 2014 2015 2014 Service cost $ 27 $ 105 $ 324 — — — Interest cost 560 1,415 641 — 444 518 Expected return on plan assets (1,008 ) (2,355 ) (506 ) — — — Amortization of loss 602 830 — — 621 541 Settlement 26,515 — — — — — Amortization of prior service cost — — — — (2,445 ) (2,447 ) Net periodic benefit cost $ 26,696 $ (5 ) $ 459 $ — $ (1,380 ) $ (1,388 )

Business Segment Information Le

Business Segment Information Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Segment Reporting Information [Line Items]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Three months ended December 31, Nine months ended December 31, 2015 2014 2015 2014 Revenues: United Kingdom $ 51,468 $ 13,421 $ 73,382 $ 38,225 United States 438,250 367,059 1,193,940 1,049,892 Other International 128,970 92,764 281,165 260,499 Total Revenues $ 618,688 $ 473,244 $ 1,548,487 $ 1,348,616
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information As a result of the Combination with Synergy, we have reassessed the organization of our business. We have concluded that we operate and report in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs. Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables. Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. Our Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities. Our Applied Sterilization Technologies segment offers a contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. The accounting policies for reportable segments are the same as those for the consolidated Company. Management evaluates performance and allocates resources based on a segment operating income measure. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which result in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare Products segment is responsible for the management of all but two manufacturing facilities and uses standard cost to sell products to the other segments. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits. Segment operating income excludes certain adjustments which include acquisition related costs, amortization of acquired intangibles, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by excluding these items they gain better insight and greater transparency of the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making. For the three and nine month periods ended December 31, 2015 , revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in Old STERIS's consolidated financial statements included in its Annual Report on Form 10-K for the year ended March 31, 2015 dated May 27, 2015 . Financial information for each of our reportable segments is presented in the following tables: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Revenues: Healthcare Products $ 317,060 $ 287,515 $ 872,028 $ 823,957 Healthcare Specialty Services 128,326 65,682 264,974 183,219 Life Sciences 82,702 67,997 210,514 185,759 Applied Sterilization Technologies 90,225 50,960 199,753 154,003 Corporate and other 375 1,090 1,218 1,678 Total revenues $ 618,688 $ 473,244 $ 1,548,487 $ 1,348,616 Segment operating income: Healthcare Products $ 52,141 $ 42,720 $ 120,674 $ 109,766 Healthcare Specialty Services 7,389 5,195 17,620 11,074 Life Sciences 24,115 16,482 58,448 41,615 Applied Sterilization Technologies 26,766 14,006 60,802 44,792 Corporate and other (2,648 ) (1,406 ) (8,580 ) (5,310 ) Total segment operating income $ 107,763 $ 76,997 $ 248,964 $ 201,937 Less: Adjustments Restructuring charges (1) $ (193 ) $ (1,076 ) $ (657 ) $ (427 ) Amortization of acquired intangible assets (2) 15,494 5,845 28,194 22,563 Acquisition and integration related charges (3) 41,726 10,860 77,254 17,556 Amortization of inventory and property "step up" to fair value (2) 4,060 22 4,102 1,310 Settlement of pension obligation (4) (46 ) — 26,470 — Loss on fair value of contingent consideration — — — 1,998 Total operating income $ 46,722 $ 61,346 $ 113,601 $ 158,937 (1) See Note 2 titled, "Restructuring" for more information related to restructuring. (2) For more information regarding our recent acquisitions see Note 18 titled, "Business Acquisitions", as well as Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015 , dated May 27, 2015 . (3) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (4) See Note 8 titled, "Benefit Plans" for more information related to the settlement of the pension obligation. Individual facilities, equipment, and intellectual properties are utilized for production by the Healthcare Products and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of these segments. Therefore, their respective amounts are reported together. December 31, 2015 March 31, 2015 Assets: Healthcare Products and Life Sciences $ 1,684,872 $ 1,261,940 Healthcare Specialty Services 753,396 396,579 Applied Sterilization Technologies 1,488,295 436,638 Total reportable segments 3,926,563 2,095,157 Corporate and other 2,521 2,134 Synergy related goodwill not yet allocated (1) 1,421,199 — Total assets $ 5,350,283 $ 2,097,291 (1) Amount is still preliminary as of December 31, 2015, as valuations have not been finalized. Goodwill will be allocated to the Healthcare Products, Healthcare Specialty Services and Applied Sterilization Technologies business segments. Nine months ended, December 31, 2015 December 31, 2014 Capital Expenditures: Healthcare Products and Life Sciences $ 22,120 $ 20,626 Healthcare Specialty Services 17,533 1,386 Applied Sterilization Technologies 42,457 34,731 Total Reportable Segments 82,110 56,743 Corporate and other 7 14 Total Capital Expenditures $ 82,117 $ 56,757 Depreciation, Depletion, and Amortization: Healthcare Products and Life Sciences $ 34,728 $ 30,900 Healthcare Specialty Services 20,142 15,961 Applied Sterilization Technologies 35,999 22,552 Total Reportable Segments 90,869 69,413 Corporate and other 56 27 Total Depreciation, Depletion, and Amortization $ 90,925 $ 69,440 Financial information for the United Kingdom, United States and other international countries is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant and equipment, net are those assets that are identified within the operations in each country or area. Three months ended December 31, Nine months ended December 31, 2015 2014 2015 2014 Revenues: United Kingdom $ 51,468 $ 13,421 $ 73,382 $ 38,225 United States 438,250 367,059 1,193,940 1,049,892 Other International 128,970 92,764 281,165 260,499 Total Revenues $ 618,688 $ 473,244 $ 1,548,487 $ 1,348,616 December 31, 2015 March 31, 2015 2015 2015 Property, Plant, and Equipment, Net United Kingdom $ 121,876 $ 12,816 United States 506,916 441,278 Other International 424,340 38,959 Property, Plant, and Equipment, Net $ 1,053,132 $ 493,053
Assets [Member]
Segment Reporting Information [Line Items]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	December 31, 2015 March 31, 2015 Assets: Healthcare Products and Life Sciences $ 1,684,872 $ 1,261,940 Healthcare Specialty Services 753,396 396,579 Applied Sterilization Technologies 1,488,295 436,638 Total reportable segments 3,926,563 2,095,157 Corporate and other 2,521 2,134 Synergy related goodwill not yet allocated (1) 1,421,199 — Total assets $ 5,350,283 $ 2,097,291
Other Expense [Member]
Segment Reporting Information [Line Items]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Nine months ended, December 31, 2015 December 31, 2014 Capital Expenditures: Healthcare Products and Life Sciences $ 22,120 $ 20,626 Healthcare Specialty Services 17,533 1,386 Applied Sterilization Technologies 42,457 34,731 Total Reportable Segments 82,110 56,743 Corporate and other 7 14 Total Capital Expenditures $ 82,117 $ 56,757 Depreciation, Depletion, and Amortization: Healthcare Products and Life Sciences $ 34,728 $ 30,900 Healthcare Specialty Services 20,142 15,961 Applied Sterilization Technologies 35,999 22,552 Total Reportable Segments 90,869 69,413 Corporate and other 56 27 Total Depreciation, Depletion, and Amortization $ 90,925 $ 69,440

Shares and Preferred Shares Lev

Shares and Preferred Shares Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Denominator (shares in thousands): Weighted average shares outstanding—basic 77,221 59,475 65,629 59,340 Dilutive effect of share equivalents 491 671 494 653 Weighted average shares outstanding and share equivalents—diluted 77,712 60,146 66,123 59,993
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 (shares in thousands) Number of share options 293 268 254 367

Share-Based Compensation Level

Share-Based Compensation Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used	The following weighted-average assumptions were used for options granted during the first nine months of fiscal 2016 and fiscal 2015 : Fiscal 2016 Fiscal 2015 Risk-free interest rate 1.51 % 1.89% Expected life of options 5.69 years 5.75 years Expected dividend yield of stock 1.40 % 1.87% Expected volatility of stock 25.06 % 29.86%
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2015 1,759,890 $ 37.03 Granted 366,700 66.88 Exercised (337,982 ) 32.25 Forfeited (37,461 ) 54.61 Canceled (500 ) 24.45 Outstanding at December 31, 2015 1,750,647 $ 43.83 6.5 years $ 55,160 Exercisable at December 31, 2015 997,531 $ 34.34 4.9 years $ 40,902
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of the non-vested restricted share activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2015 851,173 32,800 $ 42.98 Granted 277,483 22,405 68.16 Vested (205,453 ) (12,071 ) 39.73 Canceled (44,821 ) (1,493 ) 49.84 Non-vested at December 31, 2015 878,382 41,641 $ 51.61

Financial and Other Guarantees

Financial and Other Guarantees Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Schedule of Guarantor Obligations [Table Text Block]	Changes in our warranty liability during the first nine months of fiscal 2016 were as follows: Balance, March 31, 2015 $ 5,579 Warranties issued during the period 8,063 Settlements made during the period (8,138 ) Balance, December 31, 2015 $ 5,504

Derivatives and Hedging Level 3

Derivatives and Hedging Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Notes To Financial Statements [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance Sheet Location December 31, 2015 March 31, 2015 December 31, 2015 March 31, 2015 Prepaid & Other $ — $ 12 $ — $ — Accrued expenses and other $ — $ — $ 759 $ 616
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2015 2014 2015 2014 Foreign currency forward contracts Selling, general and administrative $ (380 ) $ (513 ) $ (642 ) $ (660 ) Commodity swap contracts Cost of revenues $ (159 ) $ (100 ) $ (491 ) $ 214

Fair Value Measurements Level 3

Fair Value Measurements Level 3 (Tables)	9 Months Ended
	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement Inputs, Disclosure [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at December 31, 2015 and March 31, 2015: Fair Value Measurements at December 31, 2015 and March 31, 2015 Using Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 December 31 March 31 December 31 March 31 December 31 March 31 December 31 March 31 Assets: Cash and cash equivalents (1) $ 231,360 $ 167,689 $ 207,525 $ 148,944 $ 23,835 $ 18,745 $ — $ — Forward and swap contracts (2) — 12 — — — 12 — — Investments (3) 7,579 8,332 7,579 8,332 — — — — Liabilities: Forward and swap contracts (2) $ 759 $ 616 $ — $ — $ 759 $ 616 $ — $ — Deferred compensation plans (3) 2,707 3,757 2,707 3,757 — — — — Long term debt (4) 1,639,461 621,075 — — 1,642,034 641,131 — — Contingent consideration obligations (5) 4,557 2,500 — — — — 4,557 2,500
Fair Value, by Balance Sheet Grouping [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2015 are summarized as follows: Contingent Consideration Balance at March 31, 2015 $ 2,500 Liabilities assumed as result of combination with Synergy 1,561 Additions 800 Payments (122 ) Foreign currency translation adjustments (1) (182 ) Balance at December 31, 2015 $ 4,557 (1) Reported in other comprehensive income (loss) .
Unrealized Gain (Loss) on Investments [Table Text Block]	Information regarding our investments is as follows: Investments at December 31, 2015 and March 31, 2015 Cost Unrealized Gains Unrealized Losses (2) Fair Value December 31 March 31 December 31 March 31 December 31 March 31 December 31 March 31 Available-for-sale securities: Marketable equity securities (1) $ 4,681 $ 4,681 $ 252 $ — $ — $ — $ 4,933 $ 4,681 Mutual funds 1,994 2,677 652 974 — — 2,646 3,651 Total available-for-sale securities $ 6,675 $ 7,358 $ 904 $ 974 $ — $ — $ 7,579 $ 8,332 (1) Our marketable equity securities have been in a unrealized loss position for less than 12 months. (2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Business Acquisitions (Tables)

Business Acquisitions (Tables)	9 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, (unaudited) (unaudited) 2015 2014 2015 2014 Net revenues $ 681,254 $ 638,857 $ 1,928,779 $ 1,831,740 Net income from continuing operations 45,910 39,406 118,388 111,046
Business Combination With Synergy Total Consideration [Table Text Block]	Cash consideration $ 402,494 STERIS plc shares (25,848,798 ordinary shares estimated to be issued) 1,887,479 Fair value of consideration available to vested Synergy share option holders 3,626 Total purchase consideration $ 2,293,599
Schedule of Indefinite-lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	Total (1) Useful Live Customer relationships $ 717,254 10-17 years Trade names 64,645 10 years Technology 24,627 7 years Total intangible assets acquired $ 806,526
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Purchase price allocation is still preliminary as of December 31, 2015, as valuations have not been finalized . Synergy (1) Gepco (1) Black Diamond (1) Other Acquisitions Cash $ 53,057 $ 1,108 $ — $ — Accounts receivable 104,666 4,161 2,966 3,859 Inventory 30,074 1,926 3,309 1,108 Property, plant and equipment 534,879 946 607 1,979 Other assets 19,708 1,621 43 — Intangible assets 806,526 67,189 13,500 13,631 Goodwill 1,415,274 100,782 36,654 22,093 Total assets acquired 2,964,184 177,733 57,079 42,670 Current liabilities (110,727 ) (1,473 ) (4,525 ) (1,277 ) Long-term indebtedness (321,082 ) — — — Other non-current liabilities (230,020 ) — (5,788 ) (49 ) Total liabilities assumed (661,829 ) (1,473 ) (10,313 ) (1,326 ) Net assets acquired $ 2,302,355 $ 176,260 $ 46,766 $ 41,344

Reclassifications out of AOCI40

Reclassifications out of AOCI (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015	Mar. 31, 2015
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (74,422)		$ (74,422)		$ (59,463)	$ (66,669)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax		11	$ (569)	(1,389)	$ (510)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax		(14,593)	(18,806)	(22,636)	(35,497)
Other Comprehensive Income (Loss), Net of Tax		(15,577)		7,800
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		618		(15,553)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent		(14,959)	$ (19,597)	(7,753)	$ (36,672)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[1]	(321)		(321)		(332)	1,068
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	[1]	(147)		(1,664)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[1]	158		275
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	[1]	11		(1,389)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax	[2]	7,383		7,383		7,760	(8,889)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	[2]	(837)		32,100
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	460		(15,828)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	[2]	(377)		16,272
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	[3]	(81,484)		(81,484)		$ (66,891)	$ (58,848)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	[3]	(14,593)		(22,636)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[3]	0		0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	[3]	$ (14,593)		$ (22,636)
[1]	(1) Realized gain (loss) on available for sale securities is reported in the interest income and miscellaneous expense line of the Consolidated Statements of Income.
[2]	(2) Amortization (gain) and settlement of defined benefit pension items is reported in the selling, general and administrative expense line of the Consolidated Statements of Income.
[3]	The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Property, Plant and Equipment41

Property, Plant and Equipment Level 4 (Details) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2015	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Line Items]
Asset Retirement Obligation		$ 17,402		$ 8,083
Asset Retirement Obligation, Foreign Currency Translation		(79)
Land	[1]	38,723	$ 40,668
Buildings and Improvements, Gross		440,504	263,007
Machinery and Equipment, Gross		567,633	375,555
Capitalized Computer Software, Gross		121,944	104,049
Materials, Supplies, and Other		431,697	289,778
Linen		41,552	0
Construction in Progress, Gross	[1]	87,661	47,690
Property, Plant and Equipment, Gross		1,729,714	1,120,747
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment		(676,582)	(627,694)
Property, Plant and Equipment, Net		1,053,132	$ 493,053
Asset Retirement Obligation, Liabilities Incurred		43
Asset Retirement Obligation, Accretion Expense		669
Synergy Health plc [Member]
Property, Plant and Equipment [Line Items]
Asset Retirement Obligation, Liabilities Incurred		$ 8,686
[1]	Land is not depreciated. Construction in progress is not depreciated until placed in service.

Inventories, Net Level 4 (Detai

Inventories, Net Level 4 (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Inventory, Raw Materials	$ 63,662	$ 67,095
Inventory, Work in Process	20,742	22,696
Inventory, Finished Goods	160,873	107,695
Inventory, LIFO Reserve	(17,972)	(19,071)
Inventory Valuation Reserves	(18,999)	(17,597)
Inventory, Net	$ 208,306	$ 160,818

Debt Level 4 (Details)

Debt Level 4 (Details) € in Thousands, £ in Thousands, $ in Thousands	9 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015GBP (£)	Dec. 31, 2015USD ($)	Dec. 31, 2015EUR (€)	Mar. 31, 2015USD ($)
Debt Instrument [Line Items]
Proceeds from Issuance of Private Placement	$ 350,000	$ 0
Debt Instrument, Face Amount				$ 662,460		$ 337,825
Long-term Line of Credit				977,001		283,250
Long-term Debt				1,639,461		$ 621,075
United States of America, Dollars
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding				132,000
United Kingdom, Pounds
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding | £			£ 49,000
Euro Member Countries, Euro
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding | €					€ 127,750
Term Loan Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Amount Outstanding				$ 400,000

Additional Consolidated Balan44

Additional Consolidated Balance Sheets Information Level 4 (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Employee-related Liabilities	$ 35,173	$ 16,680
Accrued Vacation	13,543	5,539
Accrued Bonuses	26,626	30,159
Accrued Liabilities for Commissions, Expense and Taxes	11,557	12,842
Defined Benefit Pension Plan, Liabilities	0	6,186
Other Postretirement Benefits Payable	2,790	2,789
Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities	1,278	610
Employee-related Liabilities, Current	90,967	74,805
Deferred Revenue	42,928	34,910
Self Insurance Reserve, Current	8,017	6,897
Accrued Sales Commission	14,090	13,591
Product Warranty Accrual	5,504	5,579
Asset Retirement Obligation, Current	0	1,092
Accrued Liabilities	152,667	102,032
Self Insurance Reserve, Noncurrent	12,052	12,052
Other Postretirement Benefits Payable, Noncurrent	16,696	18,489
Defined Benefit Pension Plan, Liabilities, Noncurrent	23,709	119
Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent	5,570	6,634
Accrued Income Taxes, Noncurrent	17,402	6,991
Other Liabilities	9,264	3,049
Other Accrued Liabilities	82,128	39,963
Other Liabilities, Noncurrent	$ 84,693	$ 47,334

Income Tax Expense Unrecognized

Income Tax Expense Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Effective Income Tax Rate, Continuing Operations	28.10%	33.00%	35.60%	35.50%
Unrecognized Tax Benefits	$ 5,521		$ 5,521

Benefit Plans Level 4 (Details)

Benefit Plans Level 4 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Sep. 30, 2015
Defined Benefit Plan Disclosure [Line Items]
DBP Purchase price of annuity contract					$ 51,805
Defined Benefit Plan, Contributions by Employer			$ 4,641
Defined Benefit Plan, Settlements, Benefit Obligation	$ 46	$ 0	26,470	$ 0
Preliminary Estimated Unfunded Benefit Obligation- Synergy Plans	23,507		23,507
United States Pension Plans of US Entity, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	35	27	105
Defined Benefit Plan, Interest Cost	0	471	560	1,415
Defined Benefit Plan, Expected Return on Plan Assets	0	(785)	(1,008)	(2,355)
Defined Benefit Plan, Amortization of Gains (Losses)	0	277	602	830
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost	0	(2)	26,696	(5)
Defined Benefit Plan, Settlements, Benefit Obligation	0	0	26,515	0
Other Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	324	0	324	0
Defined Benefit Plan, Interest Cost	641	0	641	0
Defined Benefit Plan, Expected Return on Plan Assets	(506)	0	(506)	0
Defined Benefit Plan, Amortization of Gains (Losses)	0	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost	459	0	459	0
Defined Benefit Plan, Settlements, Benefit Obligation	0	0	0	0
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	0	0	0
Defined Benefit Plan, Interest Cost	148	173	444	518
Defined Benefit Plan, Expected Return on Plan Assets	0	0	0	0
Defined Benefit Plan, Amortization of Gains (Losses)	207	180	621	541
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(815)	(816)	(2,445)	(2,447)
Defined Benefit Plan, Net Periodic Benefit Cost	(460)	(463)	(1,380)	(1,388)
Defined Benefit Plan, Settlements, Benefit Obligation	$ 0	$ 0	$ 0	$ 0

Business Segment Information 47

Business Segment Information Level 4 (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Segment Reporting Information [Line Items]
Payments to Acquire Productive Assets				$ 82,117	$ 56,757
Property, Plant and Equipment, Net		$ 1,053,132		1,053,132		$ 493,053
Assets		5,350,283		5,350,283		2,097,291
Revenues		618,688	$ 473,244	1,548,487	1,348,616
Operating Income (Loss)		46,722	61,346	113,601	158,937
Restructuring Charges	[1]	(193)	(1,076)	(657)	(427)
Restructuring Costs		(194)	(1,109)	(976)	(10)
Amortization of intangible assets acquired through acquisitions	[2]	15,494	5,845	28,194	22,563
Acquisition and integration related charges	[3]	41,726	10,860	77,254	17,556
Amortization of inventory and property step up to fair value	[2]	4,060	22	4,102	1,310
Defined Benefit Plan, Settlements, Benefit Obligation		(46)	0	(26,470)	0
Loss on fair value contingent consideration adjustment		0	0	0	1,998
Depreciation, Depletion and Amortization				90,925	69,440
Healthcare Products [Member] [Member]
Segment Reporting Information [Line Items]
Payments to Acquire Productive Assets				22,120	20,626
Revenues		317,060	287,515	872,028	823,957
Operating Income (Loss)		52,141	42,720	120,674	109,766
Depreciation, Depletion and Amortization				34,728	30,900
Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Payments to Acquire Productive Assets				42,457	34,731
Assets		1,488,295		1,488,295		436,638
Depreciation, Depletion and Amortization				35,999	22,552
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Payments to Acquire Productive Assets				82,110	56,743
Assets		3,926,563		3,926,563		2,095,157
Depreciation, Depletion and Amortization				90,869	69,413
OperatingSegmentLifeSciences [Member]
Segment Reporting Information [Line Items]
Revenues		82,702	67,997	210,514	185,759
Operating Income (Loss)		24,115	16,482	58,448	41,615
AST [Member] [Member]
Segment Reporting Information [Line Items]
Revenues		90,225	50,960	199,753	154,003
OperatingSegmentIsomedix [Member]
Segment Reporting Information [Line Items]
Operating Income (Loss)		26,766	14,006	60,802	44,792
OperatingSegmentCorpandOther [Member]
Segment Reporting Information [Line Items]
Revenues		375	1,090	1,218	1,678
Operating Income (Loss)		(2,648)	(1,406)	(8,580)	(5,310)
OperatingSegmentAll [Member]
Segment Reporting Information [Line Items]
Revenues		618,688	473,244	1,548,487	1,348,616
Operating Income (Loss)		46,722	61,346	113,601	158,937
operating income by segment		107,763	76,997	248,964	201,937
Operating Segments [Member]
Segment Reporting Information [Line Items]
Payments to Acquire Productive Assets				17,533	1,386
Assets		753,396		753,396		396,579
Revenues		128,326	65,682	264,974	183,219
Operating Income (Loss)		7,389	5,195	17,620	11,074
Depreciation, Depletion and Amortization				20,142	15,961
Corporate and Other member [Member]
Segment Reporting Information [Line Items]
Payments to Acquire Productive Assets				7	14
Assets		2,521		2,521		2,134
Depreciation, Depletion and Amortization				56	27
United Kingdom [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net		121,876		121,876		12,816
Revenues		51,468	13,421	73,382	38,225
UNITED STATES
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net		506,916		506,916		441,278
Revenues		438,250	367,059	1,193,940	1,049,892
International Member [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net		424,340		424,340		$ 38,959
Revenues		$ 128,970	$ 92,764	$ 281,165	$ 260,499
[1]	See Note 2 titled, "Restructuring" for more information related to restructuring
[2]	For more information regarding our recent acquisitions see Note 18 titled, "Business Acquisitions", as well as Old STERIS's Annual Report on Form 10-K for the year ended March 31, 2015, dated May 27, 2015.
[3]	Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

Business Segment Information De

Business Segment Information Details - Business Combinations (Details) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Business Acquisition [Line Items]
Assets		$ 5,350,283		$ 2,097,291
Pension Expense		26,470	$ 0
Operating Segments [Member]
Business Acquisition [Line Items]
Assets		753,396		396,579
Applied Sterilization Technologies [Member]
Business Acquisition [Line Items]
Assets		1,488,295		436,638
Corporate and Other [Member]
Business Acquisition [Line Items]
Assets		3,926,563		2,095,157
Corporate and Other member [Member]
Business Acquisition [Line Items]
Assets		2,521		2,134
Healthcare Products [Member] [Member]
Business Acquisition [Line Items]
Assets		1,684,872		1,261,940
Synergy Health plc [Member]
Business Acquisition [Line Items]
Goodwill, Not Allocated, Amount	[1]	$ 1,421,199		$ 0
[1]	(1) Amount is still preliminary as of December 31, 2015, as valuations have not been finalized.

Shares and Preferred Shares L49

Shares and Preferred Shares Level 4 (Details) £ / shares in Units, $ / shares in Units, £ in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015GBP (£)£ / sharesshares	Dec. 31, 2014shares	Dec. 31, 2015GBP (£)£ / sharesshares	Dec. 31, 2014shares	Dec. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Ordinary Share par value in pence received by Old STERIS shareholders resulting from the Combination | £ / shares	£ 0.10		£ 0.10
Cash value in pence by received by Synergy shareholder resulting from Combination	0.4308		0.4308		0.4308
Preferred Stock, Shares Issued	100,000		100,000		100,000	0
Preferred Stock, Redemption Price Per Share | (per share)	£ 0.10		£ 0.10		$ 0.15
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding | $ / shares					$ 0.15	$ 0
Weighted Average Number of Shares Outstanding, Basic	77,221,000	59,475,000	65,629,000	59,340,000
Weighted Average Number Diluted Shares Outstanding Adjustment	491,000	671,000	494,000	653,000
Weighted Average Number of Shares Outstanding, Diluted	77,712,000	60,146,000	66,123,000	59,993,000
Preferred shares, with £0.10 par value; 100,000 shares authorized; 100,000 issued and outstanding | $					$ 15	$ 0
Preferred Stock, Dividend Rate, Percentage	5.00%
Ordinary Share par value in pence received by Synergy shareholders in exchange resulting from the Combination | £ / shares	£ 0.10		£ 0.10
United Kingdom, Pounds
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding | £ / shares	£ 0.10		£ 0.10
Preferred shares, with £0.10 par value; 100,000 shares authorized; 100,000 issued and outstanding | £	£ 10		£ 10
United States of America, Dollars
Weighted Average Common Shares Outstanding Basic and Diluted [Line Items]
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding | $ / shares					$ 0.15
Preferred shares, with £0.10 par value; 100,000 shares authorized; 100,000 issued and outstanding | $					$ 15

Shares and Preferred Shares Com

Shares and Preferred Shares Common share options (Details) shares in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015£ / sharesshares	Dec. 31, 2014shares	Dec. 31, 2015£ / sharesshares	Dec. 31, 2014shares	Dec. 31, 2015$ / shares	Mar. 31, 2015$ / shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Ordinary Share par value in pence received by Old STERIS shareholders resulting from the Combination	£ 0.10		£ 0.10
Preferred shares, with $0.15 par value; 100,000 shares authorized; 100,000 issued and outstanding | $ / shares					$ 0.15	$ 0
Ordinary Share par value in pence received by Synergy shareholders in exchange resulting from the Combination	£ 0.10		£ 0.10
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares	293	268	254	367

Repurchases of Common Shares Le

Repurchases of Common Shares Level 4 (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Treasury Stock, Shares, Acquired	0		10,364,404
Payments for Repurchase of Common Stock	$ 14,069	$ 20,110
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	215,164

Share-Based Compensation Leve52

Share-Based Compensation Level 4 (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2015USD ($)£ / shares$ / sharesshares	Dec. 31, 2014USD ($)$ / shares	Dec. 31, 2015USD ($)	Dec. 31, 2015$ / shares	Dec. 31, 2015shares	Dec. 31, 2015	Mar. 31, 2015USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Number of ordinary shares in STERIS plc stock received by Synergy shareholder in exchange	4.39					0.4308
Remaining shares available for grant					2,202,425
Weighted-average assumptions used for options granted:
Risk-free interest rate	1.51%	1.89%
Expected life of options	5 years 8 months 9 days	5 years 9 months
Exptected dividend yield of stock	1.40%	1.87%
Expected volatility of stock	25.06%	29.86%
Estimated forfeiture rate	1.55%	1.46%
Summary of share option activity:
Number of Options, Outstanding, Beginning of Period	1,759,890
Weighted Average Exercise Price, Outstanding, Beginning of Period | $ / shares	$ 37.03
Number of Options, Granted	366,700
Weighted Average Exercise Price, Granted | $ / shares	$ 66.88
Number of Options, Exercised	(337,982)
Weighted Average Exercise Price, Exercised | $ / shares	$ 32.25
Number of Options, Forfeited	(37,461)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 54.61
Number of Options, Canceled	(500)
Weighted Average Exercise Price, Canceled | $ / shares	$ 24.45
Number of Options, Outstanding, End of Period	1,750,647
Weighted Average Exercise Price, Outstanding, End of Period | $ / shares	$ 43.83
Average Remaining Contractual Term, Outstanding	6 years 6 months
Aggregate Intrinsic Value, Outstanding | $			$ 55,160
Number of Options, Exercisable					997,531
Weighted Average Exercise Price, Exercisable | $ / shares				$ 34.34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 10 months 24 days
Aggregate Intrinsic Value, Exercisable | $			40,902
Non-vested stock options outstanding expected to vest					741,954
Common Stock, Fair Market Value Per Share | $ / shares				$ 75.34
Total intrinsic value of stock options exercised | $	$ 12,221	$ 22,289
Net cash proceeds from the exercise of stock options | $	10,908	19,245
Tax benefit from stock option exercises | $	$ 5,909	$ 8,880
Weighted average grant date fair value of stock option grants, per share | $ / shares	$ 14.66	$ 13.41
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted | $			36,581
Weighted average period for recognition of unrecognized compensation cost	2 years 3 months 18 days
Stock Appreciation Rights (SARs) [Member]
Summary of non-vested restricted share activity:
FairValueOfOutstandingStockAppreciationRights | $		$ 2,073	$ 2,527
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	851,173
Number of Restricted Shares, Granted	277,483
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 68.16
Number of Restricted Shares, Vested	(205,453)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ / shares	$ 39.73
Number of Restricted Shares, Canceled	(44,821)
Number of Restricted Shares, Non-vested at End of Period	878,382
Weighted-Average Grant Date Fair Value, Non-vested at End of Period | $ / shares	$ 42.98
Weighted-Average Grant Date Fair Value, Non-vested at End of Period | $ / shares	$ 51.61
Fair Value, Share-based Payment Awards, Other than Options | $	$ 7,913
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares	$ 49.84
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	32,800
Number of Restricted Shares, Granted	22,405
Number of Restricted Shares, Vested	(12,071)
Number of Restricted Shares, Canceled	(1,493)
Number of Restricted Shares, Non-vested at End of Period	41,641
FairValueOfOutstandingCashSettledRestrictedShareUnits | $							$ 334

Financial and Other Guarantee53

Financial and Other Guarantees Level 4 (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Guarantor Obligations [Line Items]
Product Warranty Accrual	$ 5,504	$ 5,579
Product Warranty Accrual, Warranties Issued	8,063
Standard Product Warranty Accrual, Payments	(8,138)
Service Agreements [Member]
Guarantor Obligations [Line Items]
Deferred Revenue, Current	$ 31,687	$ 30,720

Derivatives and Hedging Level 4

Derivatives and Hedging Level 4 (Details) £ in Thousands, MXN in Thousands, CAD in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015MXNlb	Dec. 31, 2015GBP (£)lb	Dec. 31, 2015USD ($)lb	Dec. 31, 2015CADlb	Mar. 31, 2015USD ($)
Derivative [Line Items]
Non-derivative Net Investment Hedge							$ 135,121
Other Assets [Member]
Derivative [Line Items]
Derivative Assets							0		$ 12
Derivative Liabilities							0		0
Accrued Liabilities [Member]
Derivative [Line Items]
Derivative Assets							0		0
Derivative Liabilities							$ 759		$ 616
Selling, General and Administrative Expenses [Member]
Derivative [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ (380)	$ (513)	$ (642)	$ (660)
Cost of Sales [Member]
Derivative [Line Items]
Gain (Loss) on Sale of Commodity Contracts	$ (159)	$ (100)	$ (491)	$ 214
212234 Copper Ore and Nickel Ore Mining [Member]
Derivative [Line Items]
Investment Contract Weight | lb					181,200	181,200	181,200	181,200
Canada, Dollars
Derivative [Line Items]
Derivative Liability, Notional Amount | CAD								CAD 9,000
Mexico, Pesos
Derivative [Line Items]
Derivative Liability, Notional Amount | MXN					MXN 90,000
Canada, Dollars
Derivative [Line Items]
Derivative Liability, Notional Amount | £						£ 4,500

Fair Value Measurements Level 4

Fair Value Measurements Level 4 (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Dec. 31, 2015		Dec. 31, 2014	Dec. 31, 2015		Dec. 31, 2014	Mar. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis		$ 6,675			$ 6,675			$ 7,358
Investments, Fair Value Disclosure		7,579			7,579			8,332
Business Combination, Contingent Consideration, Liability		4,557			4,557			2,500
Unrealized Gain on AFS Securities		904			904			974
Unrealized Loss on AFS Securities	[1]	0			0			0
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]	231,360			231,360			167,689
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]	0			0			12
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]	759			759			616
Investments, Fair Value Disclosure	[4]	7,579			7,579			8,332
Deferred Compensation Plan Assets, Fair Value	[4]	2,707			2,707			3,757
Long-term Debt, Fair Value	[5]	1,639,461			1,639,461			621,075
Business Combination, Contingent Consideration, Liability	[6]	4,557			4,557			2,500
Capital Additions [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					800
Business Combination, Consideration Transferred					1,561
Reductions and Payout [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability					(122)
Foreign Currency Gain (Loss) [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	[7]				(182)
Cost of Sales [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gain (Loss) on Sale of Commodity Contracts		(159)		$ (100)	(491)		$ 214
Equity Securities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis	[8]	4,681			4,681			4,681
Investments, Fair Value Disclosure	[8]	4,933			4,933			4,681
Unrealized Gain on AFS Securities	[8]	252			252			0
Unrealized Loss on AFS Securities	[1],[8]	0			0			0
Mutual Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Available-for-sale Securities, Amortized Cost Basis		1,994			1,994			2,677
Investments, Fair Value Disclosure		2,646			2,646			3,651
Unrealized Gain on AFS Securities		652			652			974
Unrealized Loss on AFS Securities	[1]	0			0			0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]	207,525			207,525			148,944
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]	0			0			0
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]	0			0			0
Investments, Fair Value Disclosure	[4]	7,579			7,579			8,332
Deferred Compensation Plan Assets, Fair Value	[4]	2,707			2,707			3,757
Long-term Debt, Fair Value	[5]	0			0			0
Business Combination, Contingent Consideration, Liability		0	[6]		0	[6]		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]	23,835			23,835			18,745
Foreign Currency Contract, Asset, Fair Value Disclosure	[3]	0			0			12
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]	759			759			616
Investments, Fair Value Disclosure		0	[4]		0	[4]		0
Deferred Compensation Plan Assets, Fair Value		0	[4]		0	[4]		0
Long-term Debt, Fair Value	[5]	1,642,034			1,642,034			641,131
Business Combination, Contingent Consideration, Liability		0	[6]		0	[6]		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[2]	0			0			0
Foreign Currency Contract, Asset, Fair Value Disclosure		0	[3]		0	[3]		0
Foreign Currency Contracts, Liability, Fair Value Disclosure		0	[3]		0	[3]		0
Investments, Fair Value Disclosure		0	[4]		0	[4]		0
Deferred Compensation Plan Assets, Fair Value		0	[4]		0	[4]		0
Long-term Debt, Fair Value	[5]	0			0			0
Business Combination, Contingent Consideration, Liability	[6]	$ 4,557			$ 4,557			$ 2,500
[1]	(2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.
[2]	Money market fund holdings are classified as level two as active market quoted prices are not available
[3]	The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[4]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment.
[5]	We estimate the fair value of our principal amount of long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[6]	Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
[7]	Reported in other comprehensive income (loss).
[8]	(1) Our marketable equity securities have been in a unrealized loss position for less than 12 months

Subsequent Events Level 4 (Deta

Subsequent Events Level 4 (Details) - Nov. 02, 2015	£ / shares	$ / shares
United States of America, Dollars
Subsequent Event [Line Items]
Value of transaction per Synergy Share | $ / shares		$ 38.17
United Kingdom, Pounds
Subsequent Event [Line Items]
Value of transaction per Synergy Share | £ / shares	£ 24.80

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	[1]	$ (193)	$ (1,076)	$ (657)	$ (427)
FY 2014 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		(193)	$ (1,076)	(657)		$ (427)
Restructuring and Related Cost, Cost Incurred to Date		18,815		18,815
Restructuring Reserve		1,085		1,085			$ 2,887
FY 2014 Restructuring Plan [Member] | Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date		8,095		8,095
FY 2014 Restructuring Plan [Member] | Restructuring Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date		$ 10,720		$ 10,720
[1]	See Note 2 titled, "Restructuring" for more information related to restructuring

Business Acquisitions (Details)

Business Acquisitions (Details) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
		Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2015USD ($)	Nov. 02, 2015£ / shares	Nov. 02, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue	[1]	$ 681,254	$ 638,857	$ 1,928,779	$ 1,831,740
Business Acquisition, Pro Forma Income (Loss) from Continuing Operations before Changes in Accounting and Extraordinary Items, Net of Tax	[1]	45,910	$ 39,406	118,388	$ 111,046
Synergy Combination Cash Consideration								$ 402,494
Synergy Combination Total Stock Consideration								1,887,479
FV of consideration available to vested Synergy share option holders								$ 3,626
STERIS plc total ordinary shares for consideration | shares								25,848,798
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		806,526		806,526
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	[2]	2,302,355		2,302,355
STERIS Closing Stock Price at 10/10/2014 | $ / shares								$ 73.02
Business Combination, Contingent Consideration, Liability		4,557		4,557		$ 2,500
Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability									$ 1,760
Synergy Health plc [Member]
Business Acquisition [Line Items]
Contingent liabilities Acquired Synergy Combination		7,082		7,082
Liability for Uncertain Tax Positions, Noncurrent		5,521		5,521
Approximate purchase price of entity								$ 2,289,973
Business Combination, Acquisition Related Costs				63,174
Approximate purchase price of entity								$ 2,293,599
Black Diamond [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability									800
Econopak [Member] [Member]
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs				2,379
Synergy Health plc [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	[2]	53,057		53,057
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	[2]			103,052
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	[2]	104,666		104,666
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	[2]	30,074		30,074
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	[2]	534,879		534,879
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	[2]	19,708		19,708
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	[2]	806,526		806,526
Goodwill	[2]	1,415,274		1,415,274
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	[2]	2,964,184		2,964,184
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	[2]	(110,727)		(110,727)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	[2]	321,082		321,082
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	[2]	(230,020)		(230,020)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	[2]	(661,829)		(661,829)
Operating Profit (loss) From Synergy Included in Consolidated Totals	[2]			(1,659)
Trade Names [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		64,645		64,645
Econopak [Member] [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	[2]	1,108		1,108
Approximate purchase price of entity		176,260		176,260
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	[2]	4,161		4,161
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	[2]	1,926		1,926
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	[2]	946		946
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	[2]	1,621		1,621
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	[2]	67,189		67,189
Business Acquisition, Goodwill, Expected Tax Deductible Amount	[2]	100,782		100,782
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	[2]	177,733		177,733
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	[2]	(1,473)		(1,473)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	[2]	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	[2]	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	[2]	(1,473)		(1,473)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	[2]	176,260		176,260
Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	[2]	0		0
Approximate purchase price of entity		41,344		41,344
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	[2]	3,859		3,859
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	[2]	1,108		1,108
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	[2]	1,979		1,979
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	[2]	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	[2]	13,631		13,631
Business Acquisition, Goodwill, Expected Tax Deductible Amount	[2]	22,093		22,093
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	[2]	42,670		42,670
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	[2]	(1,277)		(1,277)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	[2]	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	[2]	(49)		(49)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	[2]	(1,326)		(1,326)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	[2]	41,344		41,344
Black Diamond [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	[2]	0		0
Approximate purchase price of entity									46,766
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	[2]	2,966		2,966
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	[2]	3,309		3,309
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	[2]	607		607
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	[2]	43		43
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	[2]	13,500		13,500
Business Acquisition, Goodwill, Expected Tax Deductible Amount	[2]	36,654		36,654
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	[2]	57,079		57,079
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	[2]	(4,525)		(4,525)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt	[2]	0		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	[2]	(5,788)		(5,788)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	[2]	(10,313)		(10,313)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	[2]	46,766		46,766
Deferred Purchase Price of Acquired Entity									$ 5,870
Technology-Based Intangible Assets [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		24,627		24,627
United Kingdom, Pounds
Business Acquisition [Line Items]
Value of transaction per Synergy Share | £ / shares							£ 24.80
United States of America, Dollars
Business Acquisition [Line Items]
Value of transaction per Synergy Share | $ / shares								$ 38.17
Capital Addition Purchase Commitments [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred				1,561
Customer-Related Intangible Assets [Member] | Maximum [Member] | Synergy Health plc [Member]
Business Acquisition [Line Items]
Property, Plant and Equipment, Estimated Useful Lives						17 years
Customer-Related Intangible Assets [Member] | Minimum [Member] | Synergy Health plc [Member]
Business Acquisition [Line Items]
Property, Plant and Equipment, Estimated Useful Lives						10 years
Customer Relationships [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 717,254		$ 717,254
Trade Names [Member] | Synergy Health plc [Member]
Business Acquisition [Line Items]
Property, Plant and Equipment, Estimated Useful Lives						10 years
Technology-Based Intangible Assets [Member] | Synergy Health plc [Member]
Business Acquisition [Line Items]
Property, Plant and Equipment, Estimated Useful Lives						7 years
[1]	The historical consolidated financial information of STERIS and Synergy has been adjusted in the pro forma information to give effect to pro forma events that are (1) directly attributable to the transaction, (2) factually supportable and (3) expected to have a continuing impact on the combined results.
[2]	Purchase price allocation is still preliminary as of December 31, 2015, as valuations have not been finalized.

Related Party Transactions (Det

Related Party Transactions (Details) £ in Thousands, $ in Thousands	Dec. 31, 2015GBP (£)	Dec. 31, 2015USD ($)	Nov. 20, 2015GBP (£)	Nov. 06, 2015GBP (£)	Nov. 02, 2015USD ($)	Oct. 26, 2015GBP (£)
Related Party Transactions [Abstract]
Related party obligation to be remitted on employees behalf						£ 3,100
Related party remaining obligation	£ 1,860
Due to Related Parties			£ 3,100
Related Party Cash proceeds received in exchange for Synergy Holdings				£ 1,250
Related Party- Outstanding obligation after cash proceeds retained and applied to balance				£ 1,860
Notes Receivable, Related Parties | $		$ 368
Due from Related Parties, Current | $		$ 3,117			$ 5,152